FlexGen to Use VC Money to Speed Commercialization of FlexArrayer | GenomeWeb

NEW YORK (GenomeWeb News) – FlexGen today announced that it has closed a round of private equity financing with an undisclosed amount of funding coming from BioGeneration Ventures and Crédit Agricole Private Equity.

The amount of the funding was in the several million euros, according to FlexGen CEO Fred Dom.

The firm, based in Leiden, The Netherlands, intends to use the money to speed up development and global commercialization of its FlexArrayer for producing custom microarrays.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.